J Neurol Res

Journal of Neurology Research, ISSN 1923-2845 print, 1923-2853 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Neurol Res and Elmer Press Inc

Journal website https://www.neurores.org

Short Communication

Volume 000, Number 000, January 2024, pages 000-000

Non-Invasive Neuromodulation for Episodic and Chronic Migraine Headache: Preliminary Findings on Feasibility of At-Home Transcranial Direct Current Stimulation With Remote Supervision

**Table 1.** Baseline Characteristics (N = 22)
Characteristics	Median (IQR) or N (%)
^aRace analyses are White, Non-Hispanic vs. African American, Hispanic or Asian. ^bEducation analyses are completed high school and some college vs. completed college and graduate school. MSQ: Migraine-Specific Quality of Life; Ham-D: Hamilton Depression Scale; KPS: Karnofsky Performance Status: (100 - Normal, no complaints, no evidence of disease; 90 - Able to carry on normal activity, minor signs or symptoms of disease; 80 - Normal activity with effort, some signs or symptoms of disease; 70 - Cares for self, unable to carry on normal activity or do work).
Demographics
Age	37 (27 - 46)
Gender	17 F, 5 M
Race^a
White, non-Hispanic	15 (68%)
African American	2 (9%)
Hispanic	3 (14%)
Asian	2 (9%)
Education^b
Completed high school	1 (5%)
Some college	4 (18%)
Completed college	16 (73%)
Graduate school	1 (5%)
Marital status
Single	14 (64%)
Married or living with partner	8 (36%)
Clinical characteristics
Migraine duration (years)	17 (10 - 29)
Chronic migraine status
Episodic	7 (32%)
Chronic	15 (68%)
KPS
70	1 (5%)
80	8 (37%)
90	12 (55%)
100	1 (5%)
Baseline diary data/30 days
Migraine days	23 (11 - 28)
Migraine attacks	5 (2 - 6)
Acute medication days	6 (1 - 16)
Acute medication doses	11 (2 - 28)
Average migraine pain intensity	5 (4 - 6)
Aura days	0 (0 - 2)
Nausea days	2 (0 - 6)
Photophobia days	8 (2 - 24)
Phonophobia days	6 (2 - 16)
MSQ total	42 (38 - 48)
MSQ role restriction	23 (21 - 29)
MSQ role prevention	9 (6 - 11)
MSQ emotion function	10 (8 - 12)
Ham-D	9 (4 - 13)

Table 1. Baseline Characteristics (N = 22)

Characteristics

Median (IQR) or N (%)

^aRace analyses are White, Non-Hispanic vs. African American, Hispanic or Asian. ^bEducation analyses are completed high school and some college vs. completed college and graduate school. MSQ: Migraine-Specific Quality of Life; Ham-D: Hamilton Depression Scale; KPS: Karnofsky Performance Status: (100 - Normal, no complaints, no evidence of disease; 90 - Able to carry on normal activity, minor signs or symptoms of disease; 80 - Normal activity with effort, some signs or symptoms of disease; 70 - Cares for self, unable to carry on normal activity or do work).

Demographics

Age

37 (27 - 46)

Gender

17 F, 5 M

Race^a

White, non-Hispanic

15 (68%)

African American

2 (9%)

Hispanic

3 (14%)

Asian

2 (9%)

Education^b

Completed high school

1 (5%)

Some college

4 (18%)

Completed college

16 (73%)

Graduate school

1 (5%)

Marital status

Single

14 (64%)

Married or living with partner

8 (36%)

Clinical characteristics

Migraine duration (years)

17 (10 - 29)

Chronic migraine status

Episodic

7 (32%)

Chronic

15 (68%)

KPS

1 (5%)

8 (37%)

12 (55%)

100

1 (5%)

Baseline diary data/30 days

Migraine days

23 (11 - 28)

Migraine attacks

5 (2 - 6)

Acute medication days

6 (1 - 16)

Acute medication doses

11 (2 - 28)

Average migraine pain intensity

5 (4 - 6)

Aura days

0 (0 - 2)

Nausea days

2 (0 - 6)

Photophobia days

8 (2 - 24)

Phonophobia days

6 (2 - 16)

MSQ total

42 (38 - 48)

MSQ role restriction

23 (21 - 29)

MSQ role prevention

9 (6 - 11)

MSQ emotion function

10 (8 - 12)

Ham-D

9 (4 - 13)

**Table 2.** Adherence to the Prescribed 60-Day Intervention (N = 16)
	Stimulation days, mean (SD)	Stimulation days, range	Stimulation days, median	Adherence ≥ 80% of delivered sessions, N (%)	Adherence 100% of delivered sessions, N (%)
SD: standard deviation.
Month 1	25.7 (5.2)	10 - 30	27.5	12 (75%)	4 (25%)
Month 2	23.6 (8.8)	3 - 30	27.5	11 (68.8%)	4 (25%)
Total 60-day period	49.3 (13.2)	13 - 60	52.5	11 (68.8%)	4 (25%)

Table 2. Adherence to the Prescribed 60-Day Intervention (N = 16)

Stimulation days, mean (SD)

Stimulation days, range

Stimulation days, median

Adherence ≥ 80% of delivered sessions, N (%)

Adherence 100% of delivered sessions, N (%)

SD: standard deviation.

Month 1

25.7 (5.2)

10 - 30

27.5

12 (75%)

4 (25%)

Month 2

23.6 (8.8)

3 - 30

27.5

11 (68.8%)

4 (25%)

Total 60-day period

49.3 (13.2)

13 - 60

52.5

11 (68.8%)

4 (25%)